2023
DOI: 10.1016/s1473-3099(22)00291-2
|View full text |Cite
|
Sign up to set email alerts
|

Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
193
0
7

Year Published

2023
2023
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 246 publications
(201 citation statements)
references
References 81 publications
1
193
0
7
Order By: Relevance
“…There are currently a number of paediatric and maternal RSV vaccines approaching clinical translation, with the World Health Organisation predicting vaccine release within 5–10 years 6 and regulatory approval for long‐acting monoclonal antibody prophylaxis expected within 1 year 34 . Important areas for exploration include the development of vaccines for infants <6 months with immunity enduring across childhood and maternal vaccines for transplacental protection 6,32 .…”
Section: Rsv Prevention: Current and Future Interventionsmentioning
confidence: 99%
“…There are currently a number of paediatric and maternal RSV vaccines approaching clinical translation, with the World Health Organisation predicting vaccine release within 5–10 years 6 and regulatory approval for long‐acting monoclonal antibody prophylaxis expected within 1 year 34 . Important areas for exploration include the development of vaccines for infants <6 months with immunity enduring across childhood and maternal vaccines for transplacental protection 6,32 .…”
Section: Rsv Prevention: Current and Future Interventionsmentioning
confidence: 99%
“…Pre-F displays six major antigenic sites (Ø, I, II, III, IV, and V), whereas only four of these sites (I, II, III, and IV) are retained after transition to post-F (10). Before the stabilization of pre-F, many F-based vaccine candidates in clinical testing used post-F as the vaccine antigen, given its high stability; however, no post-F vaccine candidates have advanced to licensure (18,19). The stabilization and structural characterization of pre-F led to the identification of highly neutralization-sensitive epitopes (sites Ø and V) exclusive to the pre-F surface, motivating efforts to use pre-F as a vaccine antigen capable of eliciting high titers of neutralizing antibody (10,11,(20)(21)(22)(23)(24)(25).…”
Section: Introductionmentioning
confidence: 99%
“…Moreover, RSV, although initially considered to be a virus of infancy only, turned out to be one of the major infective factors in adults, especially in the elderly [ 7 , 8 , 9 ]; despite a limited access to viral testing and often unspecific clinical picture of RSV RTI, the awareness of the significance of RSV is growing [ 10 ]. The high frequency and severity of the RSV disease translate into a huge socioeconomic impact and utilization of healthcare resources seen in paediatric and adult population [ 7 , 11 , 12 , 13 ], urging a development of monoclonal antibodies and vaccines targeting infants, pregnant women and older adults [ 14 ]. A relationship between lower air quality and RSV infections was observed mainly in hospital-based and some community-based studies [ 15 , 16 , 17 , 18 , 19 , 20 , 21 ], with particular interest in PM 2.5 [ 17 , 18 , 21 ], PM 10 [ 15 , 21 ], nitric dioxide (NO 2 ) [ 21 ], ozone [ 22 ], carbon monoxide (CO) [ 20 ], and benzene [ 19 ].…”
Section: Introductionmentioning
confidence: 99%